GO:0006188 IMP biosynthetic process: Purine Nucleotide Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0006188 (IMP biosynthetic process) describes the chemical reactions and pathways that build inosine monophosphate (IMP), the first fully formed purine nucleotide and the branch-point precursor of AMP and GMP.
• IMP biosynthesis is a central metabolic node because IMP is the common precursor for both adenine and guanine nucleotides, which are required for DNA, RNA, ATP, GTP, and cofactor synthesis.
• The terminal step of de novo IMP biosynthesis is catalyzed by IMP dehydrogenase (IMPDH), and its activity is tightly coupled to cell-cycle progression and tumor growth.
• IMPDH2 dephosphorylation downstream of FGFR signaling promotes S-phase progression, linking IMP biosynthetic flux directly to proliferation control.
• Parasite-specific IMP-processing enzymes, such as Plasmodium falciparum IMP-specific nucleotidase, illustrate how the pathway can be targeted in infectious disease.
• Gut microbial metabolites such as imidazole propionate intersect with purine-related metabolic signaling and have been linked to Alzheimer's disease pathology and obesity models.
Description
GO:0006188, IMP biosynthetic process, is the biological process by which cells produce inosine monophosphate (IMP), the first complete purine nucleotide in the de novo purine biosynthetic route. IMP is not merely an intermediate: it is the central branch-point metabolite from which both adenosine and guanosine nucleotides are derived, making this process essential for nucleic acid synthesis, energy metabolism, and cofactor production. Because rapidly dividing cells must sustain high purine flux, IMP biosynthesis is mechanistically coupled to growth-factor signaling and cell-cycle progression. Understanding GO:0006188 therefore matters for cancer biology, metabolic disease, neurobiology, and antiparasitic drug discovery. From a research perspective, IMP biosynthetic process is studied with a combination of metabolic flux analysis, enzyme kinetics, structural biology, and CRISPR-based perturbation of pathway genes. The pathway is also relevant to translational questions: for example, IMPDH2 dephosphorylation under FGFR signaling promotes S-phase progression and tumor growth, directly connecting IMP biosynthetic capacity to proliferation. In parallel, parasite enzymes that process IMP, such as Plasmodium falciparum IMP-specific nucleotidase, have been structurally and catalytically characterized as potential drug targets. This article summarizes the authoritative QuickGO definition of GO:0006188, the major enzymatic steps and regulatory logic of the pathway, the key genes and proteins involved, and the experimental models and CRISPR strategies used to interrogate it. All mechanistic and disease claims are anchored to published literature, and the reference list is generated from the verified citations cited in the text.
IMP biosynthetic process At A Glance
| GO ID | GO:0006188 |
|---|---|
| GO term | IMP biosynthetic process |
| Ontology | biological_process |
| Synonym | IMP anabolism; IMP biosynthesis; IMP formation; IMP synthesis |
| Definition | The chemical reactions and pathways resulting in the formation of IMP, inosine monophosphate. |
| Major function | De novo synthesis of inosine monophosphate, the first complete purine nucleotide and precursor of AMP and GMP. |
| Key terminal enzyme | IMPDH (IMP dehydrogenase), which catalyzes the NAD+-dependent oxidation of XMP to IMP in the de novo route. |
| Pathway position | Central branch-point of purine nucleotide biosynthesis, feeding both adenine and guanine nucleotide pools. |
| Disease relevance | Cancer proliferation, metabolic disease, neurodegeneration, and parasitic infections. |
What Is GO:0006188?
According to the QuickGO definition, GO:0006188 (IMP biosynthetic process) refers to the chemical reactions and pathways resulting in the formation of IMP, inosine monophosphate. In practical terms, it covers the enzymatic steps that convert simple precursors such as PRPP, glycine, glutamine, aspartate, and formyl-THF into the purine ring of IMP, as well as the terminal oxidation step that yields IMP itself. The term is a biological_process child of purine ribonucleotide biosynthetic process and is synonymous with IMP anabolism, IMP biosynthesis, IMP formation, and IMP synthesis. Because IMP is the first nucleotide with a complete purine ring, its biosynthesis defines the entry point into the purine nucleotide pool and feeds both AMP and GMP branches.
Why Is IMP biosynthetic process Important in Cell Biology?
IMP biosynthetic process is important because it supplies the first complete purine nucleotide, IMP, from which all adenine and guanine nucleotides are subsequently derived. Without sufficient IMP biosynthesis, cells cannot maintain DNA and RNA synthesis, ATP and GTP pools, or purine-dependent cofactors, and proliferating cells are especially sensitive to perturbations in this pathway. The pathway is also a therapeutic vulnerability: IMPDH2 activity and its phosphorylation state are directly linked to S-phase progression and tumor growth under FGFR signaling, and parasite IMP-processing enzymes are validated antiparasitic targets. In addition, microbial metabolites that intersect with purine-related metabolic signaling, such as imidazole propionate, have been associated with Alzheimer's disease pathology and with lipid metabolism in obesity models, underscoring the broader physiological reach of purine metabolic processes.
• Provides IMP, the first complete purine nucleotide and obligate precursor of AMP and GMP.
• Supports DNA replication, RNA transcription, and ATP/GTP energy metabolism in proliferating cells.
• Couples growth-factor signaling to cell-cycle progression via IMPDH2 phosphorylation and dephosphorylation.
• Represents a metabolic vulnerability in tumors with deregulated FGFR signaling.
• Offers parasite-selective drug targets such as Plasmodium falciparum IMP-specific nucleotidase.
• Intersects with gut microbial metabolite signaling relevant to Alzheimer's disease pathology.
• Connects to lipid metabolism and obesity through imidazole propionate and PPAR signaling.
• Serves as a model pathway for studying enzyme regulation via cystathionine beta-synthase domains.
• Is a core component of purine homeostasis required for nucleotide pool balance.
• Enables metabolic flux and CRISPR perturbation studies that link genotype to nucleotide output.
What Happens During IMP biosynthetic process?
Overview of the de novo purine route to IMP
In simple terms: Cells build the purine ring of IMP step by step from small precursor molecules.
IMP biosynthetic process is the segment of purine metabolism that assembles the purine ring and terminates in IMP. The pathway consumes PRPP, glycine, glutamine, aspartate, and formyl-THF derivatives, and it is energetically expensive, which is why it is tightly regulated and coupled to the proliferative state of the cell. Because IMP is the first nucleotide with a complete purine ring, its formation marks the transition from precursor metabolism to nucleotide metabolism and sets the stage for AMP and GMP synthesis.
Terminal oxidation step catalyzed by IMPDH
In simple terms: The last step of the pathway uses IMP dehydrogenase to convert an intermediate into IMP.
The terminal step of de novo IMP biosynthesis is catalyzed by IMP dehydrogenase (IMPDH), which performs an NAD+-dependent oxidation to yield IMP. IMPDH activity is therefore a direct readout of IMP biosynthetic capacity, and its regulation has functional consequences for nucleotide pool size and cell-cycle progression. In cancer cells, IMPDH2 dephosphorylation under FGFR signaling promotes S-phase progression and tumor growth, demonstrating that the terminal step of IMP biosynthesis is not constitutive but signal-responsive.
IMP as the branch-point precursor of AMP and GMP
In simple terms: IMP is the shared starting material for making both adenine and guanine nucleotides.
Once IMP is produced, it serves as the common precursor for both AMP and GMP, making GO:0006188 a central node in purine nucleotide biosynthesis. This branch-point position means that flux through IMP biosynthesis influences the balance of adenine and guanine nucleotides, which in turn affects DNA synthesis, RNA synthesis, and GTP-dependent signaling. Consequently, perturbations of IMP biosynthetic enzymes can produce pleiotropic effects on nucleotide homeostasis and proliferation.
Enzyme regulation via cystathionine beta-synthase domains
In simple terms: Some pathway enzymes are switched on or off by regulatory modules attached to them.
Enzymes in nucleotide metabolism can be regulated through cystathionine beta-synthase (CBS) domains, which act as sensory modules that modulate catalytic activity in response to cellular cues. This mode of regulation is relevant to understanding how IMP biosynthetic flux can be adjusted without changing enzyme abundance. Such regulatory logic helps explain why pathway output can change rapidly during proliferation or stress.
Parasite IMP-processing enzymes as pathway variants
In simple terms: Some parasites use specialized enzymes to handle IMP, which can be exploited as drug targets.
Plasmodium falciparum expresses an IMP-specific nucleotidase whose structure and catalytic regulation have been characterized, illustrating that IMP-processing steps can be organism-specific. These parasite enzymes differ sufficiently from human counterparts to be attractive antiparasitic targets. Studying them provides insight into the evolutionary plasticity of IMP-related biochemistry within the broader conceptual space of GO:0006188.
Key Genes Involved in GO:0006188 IMP biosynthetic process
The following genes and proteins are experimentally implicated in IMP biosynthetic process or in the immediate processing and regulation of IMP, based on the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| IMPDH2 | Catalyzes the terminal NAD+-dependent oxidation step that yields IMP; regulated by phosphorylation | Central to linking IMP biosynthetic flux to S-phase progression and tumor growth |
| IMPDH1 | IMP dehydrogenase isoform involved in IMP biosynthesis and nucleotide pool maintenance | Relevant to comparative studies of IMPDH isoform-specific regulation |
| FGFR | Growth-factor receptor whose signaling controls IMPDH2 phosphorylation state | Upstream regulator connecting extracellular signals to IMP biosynthesis |
| PPAT | Phosphoribosyl pyrophosphate amidotransferase, the committed step of de novo purine biosynthesis feeding IMP | Target for flux control studies upstream of IMP formation |
| GART | Trifunctional enzyme of de novo purine biosynthesis contributing to IMP assembly | Model for multi-domain purine pathway enzymes |
| PFAS | Formylglycinamidine ribonucleotide synthase in the de novo purine route to IMP | Relevant to glutamine-dependent steps of IMP biosynthesis |
| PAICS | Bifunctional enzyme in the de novo purine pathway that contributes to IMP formation | Studied for its role in nucleotide supply in proliferating cells |
| ATIC | Bifunctional enzyme catalyzing the final two steps of de novo IMP biosynthesis | Key node for understanding terminal IMP formation |
| ADSL | Adenylosuccinate lyase, which also participates in purine biosynthesis upstream of IMP | Relevant to purine pathway deficiencies and flux analysis |
| CBS-domain enzymes | Regulatory modules that modulate nucleotide metabolic enzyme activity | Model system for allosteric and sensory regulation of IMP-related enzymes |
| Plasmodium IMP-specific nucleotidase | Parasite enzyme that processes IMP and is structurally characterized | Antiparasitic drug target and evolutionary comparison to human enzymes |
| Imidazole propionate-related microbial enzymes | Gut microbial metabolic machinery producing imidazole propionate, a purine-related metabolite | Links microbial metabolism to host purine-related signaling |
| mTORC1 pathway components | Coordinate nutrient sensing with protein synthesis machinery and nucleotide demand | Context for how IMP biosynthesis supports proliferative anabolism |
| tRNA wobble modification enzymes | Support translation fidelity and protein synthesis capacity alongside nucleotide supply | Relevant to coupling IMP biosynthesis with translation |
| Extracellular vesicle secretome markers | Report on manufacturing and quality attributes of cell-derived products | Context for translational and manufacturing workflows around metabolic cell models |
| Parvovirus entry pathway proteins | Model for studying viral entry mechanisms in cultured cells | General cell-biology context for pathway perturbation studies |
How Is IMP biosynthetic process Regulated?
IMP biosynthetic process is regulated at multiple levels. At the signaling level, FGFR signaling controls the phosphorylation state of IMPDH2, and dephosphorylation of IMPDH2 promotes S-phase progression and tumor growth, directly linking growth-factor input to IMP biosynthetic capacity. At the enzyme level, regulatory modules such as cystathionine beta-synthase domains can modulate the activity of nucleotide metabolic enzymes, providing a mechanism for rapid adjustment of pathway flux. At the systems level, nutrient-sensing pathways such as mTORC1 cooperate with tRNA wobble modification to sustain the protein synthesis machinery, reflecting the broader coupling between nucleotide supply and anabolic demand. Together, these layers ensure that IMP production matches the proliferative and biosynthetic needs of the cell.
IMP biosynthetic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| IMPDH2 | Cancer proliferation and S-phase progression under FGFR signaling | IMPDH2 point-mutation or phospho-mutant knock-in in cancer cell lines |
| FGFR | Growth-factor-driven tumors with altered IMP biosynthesis | FGFR overexpression or constitutive-active knock-in models |
| Plasmodium IMP-specific nucleotidase | Parasitic infection and antiparasitic drug discovery | Recombinant enzyme assays and parasite knockout models |
| Microbial imidazole propionate pathway | Alzheimer's disease pathology and obesity-related lipid metabolism | Gnotobiotic animal models and adipocyte overexpression systems |
| mTORC1 pathway components | Nutrient-sensing and protein synthesis in proliferative disease | mTORC1 knockout or point-mutation cell models |
Cancer and proliferative signaling
IMP biosynthetic process is directly implicated in cancer because IMPDH2 dephosphorylation under FGFR signaling promotes S-phase progression and tumor growth. This places the terminal step of IMP biosynthesis downstream of a major oncogenic receptor pathway and suggests that tumors with active FGFR signaling may depend on sustained IMP production. Targeting IMP biosynthetic flux is therefore a rational strategy for disrupting nucleotide supply in proliferating tumor cells.
Neurodegeneration and microbial metabolites
Gut bacterial metabolite imidazole propionate potentiates Alzheimer's disease pathology, indicating that microbial metabolic products intersecting with purine-related signaling can influence neurodegeneration. Although imidazole propionate is not IMP itself, its study highlights how metabolites in the purine-related metabolic space can affect neuronal function and disease progression. This creates a conceptual bridge between microbial metabolism, purine biochemistry, and neurodegenerative disease research.
Metabolic disease and obesity
Imidazole propionate ameliorates lipid metabolism in adipocytes to attenuate high-fat diet-induced obesity via PPAR signaling, demonstrating that purine-related microbial metabolites can modulate systemic metabolic phenotypes. These findings connect purine-associated metabolic pathways to lipid handling and energy balance. They also motivate studies of how IMP biosynthetic process and related nucleotide metabolism intersect with metabolic disease models.
Parasitic infections
Plasmodium falciparum IMP-specific nucleotidase has been structurally and catalytically characterized, establishing parasite IMP-processing enzymes as potential drug targets. Because these enzymes differ from human counterparts, they offer selectivity for antiparasitic intervention. This illustrates how the biochemistry surrounding IMP can be exploited therapeutically in infectious disease.
From IMP biosynthetic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is IMPDH2 required for S-phase progression? | IMPDH2 knockout cell line with cell-cycle profiling |
| Does IMPDH2 phosphorylation state control tumor growth? | Phospho-mutant point-mutation knock-in of IMPDH2 |
| Does FGFR signaling regulate IMP biosynthetic flux? | FGFR constitutive-active knock-in or overexpression model |
| Can parasite IMP-processing enzymes be selectively inhibited? | Recombinant Plasmodium IMP-specific nucleotidase assays and parasite KO |
| How does imidazole propionate affect neuronal pathology? | Microbial metabolite exposure in neuronal cell models and animal models |
| Does imidazole propionate alter adipocyte lipid handling? | Adipocyte overexpression and PPAR-pathway reporter models |
How to Study the IMP biosynthetic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| LC-MS metabolomics | Levels of IMP and related purine nucleotides | Quantifying pathway output after gene perturbation |
| Stable-isotope tracing | De novo flux into IMP and downstream nucleotides | Distinguishing synthesis from salvage |
| Flow cytometry cell-cycle analysis | S-phase progression and proliferation | Testing IMPDH2 mutants and FGFR signaling effects |
| Enzyme kinetics assays | Catalytic activity and substrate specificity of IMP-processing enzymes | Characterizing parasite and human enzymes |
| Structural biology (crystallography/cryo-EM) | Three-dimensional structure and regulatory sites | Informing inhibitor design |
| Microbial metabolite exposure assays | Host-cell responses to imidazole propionate | Modeling microbiome-host metabolic interactions |
| CRISPR perturbation screens | Gene requirements for IMP biosynthetic fitness | Identifying pathway dependencies in cancer cells |
| Western blotting for phospho-IMPDH2 | Phosphorylation state of IMPDH2 | Monitoring FGFR-dependent regulation |
Metabolic flux and nucleotide quantification
Measuring IMP and downstream purine nucleotides by LC-MS-based metabolomics or targeted nucleotide quantification allows researchers to assess flux through IMP biosynthetic process. Stable-isotope tracing from labeled precursors can distinguish de novo synthesis from salvage and can reveal how IMPDH2 perturbation changes pathway output. These approaches are essential for linking genetic perturbations to actual metabolic flux.
Cell-cycle and proliferation assays
Because IMPDH2 dephosphorylation promotes S-phase progression, cell-cycle analysis by flow cytometry and proliferation assays are standard readouts for IMP biosynthetic function. Combining these assays with IMPDH2 mutants allows researchers to test whether a specific phosphorylation site is required for S-phase entry. Such experiments connect molecular pathway activity to a phenotypic outcome.
Structural and enzymatic characterization
Structural biology and enzyme kinetics are used to characterize IMP-processing enzymes, as demonstrated for Plasmodium falciparum IMP-specific nucleotidase. These methods reveal catalytic mechanisms, substrate specificity, and regulatory features that can inform inhibitor design. They are also useful for comparing parasite and human enzymes to assess selectivity.
Microbial metabolite and host-cell interaction studies
Studies of imidazole propionate use microbial metabolite exposure in host cell and animal models to assess effects on disease pathology and metabolism. These approaches integrate microbiome-derived chemistry with host purine-related signaling. They are relevant for understanding how environmental metabolites intersect with nucleotide metabolic pathways.
How CRISPR Can Be Used to Study GO:0006188 IMP biosynthetic process
Knockout
CRISPR knockout of IMPDH2 or upstream purine pathway genes can be used to test whether IMP biosynthetic process is required for proliferation and S-phase progression. Knockout clones are compared with parental cells in nucleotide quantification and cell-cycle assays to establish causality. This approach is foundational for determining pathway dependency in cancer models.
Point Mutation
Point-mutation knock-in of specific IMPDH2 phosphorylation sites allows researchers to test whether phosphorylation or dephosphorylation is required for S-phase progression and tumor growth. By introducing phospho-null or phospho-mimetic mutations, the regulatory logic downstream of FGFR signaling can be dissected. This provides mechanistic resolution beyond simple knockout.
Knock-in
Knock-in of tagged or reporter alleles at IMPDH2 or related loci enables tracking of protein localization, stability, and interaction partners in live cells. Tagged knock-in models are also useful for monitoring pathway enzyme dynamics under growth-factor stimulation. These models support precise biochemical and imaging studies of IMP biosynthesis.
Overexpression
Overexpression of IMPDH2, FGFR, or parasite IMP-processing enzymes can be used to test sufficiency for increased IMP flux, proliferation, or drug sensitivity. Overexpression models are particularly useful for validating gain-of-function hypotheses and for producing recombinant enzyme for structural studies. They complement loss-of-function CRISPR approaches.
How EDITGENE Supports IMP biosynthetic process Research
Researchers studying IMP biosynthetic process-related genes often need to determine whether a candidate gene is causally involved in pathway output, proliferation, or disease phenotypes. Establishing causality requires controlled genetic perturbation, ideally with isogenic models that differ only at the locus of interest. EDITGENE provides the full range of CRISPR-engineered cell models needed to interrogate GO:0006188 and its regulatory network.
Contact EDITGENE today to design your custom CRISPR model for IMP biosynthetic process research.
Frequently Asked Questions About IMP biosynthetic process
What is IMP biosynthetic process?
IMP biosynthetic process (GO:0006188) is the set of chemical reactions and pathways that produce inosine monophosphate (IMP), the first complete purine nucleotide and the precursor of AMP and GMP.
What genes are involved in IMP biosynthetic process?
Key genes include IMPDH2, which catalyzes the terminal step, along with upstream purine pathway enzymes and signaling regulators such as FGFR.
Why is IMP important for cells?
IMP is the branch-point precursor for both adenine and guanine nucleotides, which are required for DNA, RNA, ATP, and GTP synthesis.
How is IMP biosynthetic process regulated?
It is regulated by growth-factor signaling that controls IMPDH2 phosphorylation, by regulatory domains such as cystathionine beta-synthase domains, and by nutrient-sensing pathways.
Is IMP biosynthetic process involved in cancer?
Yes, IMPDH2 dephosphorylation under FGFR signaling promotes S-phase progression and tumor growth, linking IMP biosynthesis to cancer proliferation.
What diseases are linked to IMP metabolism?
IMP-related metabolism has been linked to cancer, Alzheimer's disease pathology, obesity-related lipid metabolism, and parasitic infections.
How do researchers study IMP biosynthetic process?
Common methods include LC-MS metabolomics, stable-isotope tracing, cell-cycle assays, enzyme kinetics, structural biology, and CRISPR perturbation.
Can CRISPR be used to study IMP biosynthetic process?
Yes, CRISPR knockout, point-mutation knock-in, tagged knock-in, and overexpression models are used to test the causal role of IMP pathway genes.
What is the terminal step of IMP biosynthesis?
The terminal step is catalyzed by IMP dehydrogenase (IMPDH), which performs an NAD+-dependent oxidation to yield IMP.
Are there parasite-specific IMP enzymes?
Yes, Plasmodium falciparum expresses an IMP-specific nucleotidase that has been structurally and catalytically characterized as a potential drug target.
Conclusion
GO:0006188 (IMP biosynthetic process) defines the production of inosine monophosphate, the first complete purine nucleotide and the central branch-point precursor of AMP and GMP. Its terminal enzyme IMPDH2 is regulated by FGFR-dependent phosphorylation and is directly linked to S-phase progression and tumor growth, making the pathway a compelling target for cancer and metabolic research. Beyond oncology, IMP-related biochemistry intersects with neurodegeneration, obesity-related lipid metabolism, and parasitic infections, as illustrated by studies of imidazole propionate and Plasmodium IMP-specific nucleotidase. Because the pathway is both metabolically central and signal-responsive, rigorous causal studies require precise genetic models. CRISPR knockout, point-mutation, knock-in, and overexpression cell lines, combined with metabolomics, cell-cycle assays, and structural enzymology, provide the toolkit needed to dissect IMP biosynthetic process in health and disease.
References
- 1. Vemuganti V et al.. 2026. Gut bacterial metabolite imidazole propionate potentiates Alzheimer's disease pathology.. Nat Commun 17(1) PMID: 42362546
- 2. Hermann J et al.. 2025. mTORC1 cooperates with tRNA wobble modification to sustain the protein synthesis machinery.. Nat Commun 16(1):4201 PMID: 40328729
- 3. Humbert C et al.. 2025. GMP-Compliant Process for the Manufacturing of an Extracellular Vesicles-Enriched Secretome Product Derived From Cardiovascular Progenitor Cells Suitable for a Phase I Clinical Trial.. J Extracell Vesicles 14(8):e70145 PMID: 40831309
- 4. Lin C et al.. 2025. Imidazole propionate ameliorates lipid metabolism in adipocytes to attenuate high-fat diet-induced obesity via PPAR signaling pathway.. Lipids Health Dis 24(1):356 PMID: 41204354
- 5. Zhou B et al.. 2025. IMPDH2 dephosphorylation under FGFR signaling promotes S-phase progression and tumor growth.. Cell Rep 44(1):115116 PMID: 39739531
- 6. Shi J et al.. 2023. Progress in the study of parvovirus entry pathway.. Virol J 20(1):61 PMID: 37016419
- 7. Anashkin VA et al.. 2017. Enzymes Regulated via Cystathionine β-Synthase Domains.. Biochemistry (Mosc) 82(10):1079-1087 PMID: 29037129
- 8. Carrique L et al.. 2020. Structure and catalytic regulation of Plasmodium falciparum IMP specific nucleotidase.. Nat Commun 11(1):3228 PMID: 32591529
